Dow Jones

40 211,72

0,53%

DAX

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
17/06/2011	08h30	Business Wire	Data Suggests Treatment with FOLOTYN® Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Rela...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2011	08h30	Business Wire	COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/06/2011	15h00	Business Wire	FOLOTYN® Data to be Presented at the Congress of the European Hematology Association & the International Conference on Malig...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/06/2011	21h57	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/05/2011	18h49	Zacks	Risk-Reward Balanced at Allos - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/05/2011	22h14	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/05/2011	18h55	Zacks	1Q Loss Narrows at Allos - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/05/2011	23h24	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/05/2011	22h05	Business Wire	Allos Therapeutics and Mundipharma Announce Strategic Collaboration for FOLOTYN	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/05/2011	22h00	Business Wire	Allos Therapeutics Reports First Quarter 2011 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/05/2011	20h42	Zacks	Mixed Results for CELG's Revlimid - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/05/2011	14h00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences in May	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/05/2011	14h00	Business Wire	Allos Therapeutics to Report First Quarter 2011 Results on May 10, 2011	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/05/2011	14h16	Marketwired	Oncology Drug Makers Positioned for Long Term Growth	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	22h48	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	18h35	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (DEFA14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/04/2011	18h31	Edgar (US Regulatory)	Proxy Statement (definitive) (DEF 14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/04/2011	19h01	Zacks	Allos Therapeutics at Neutral - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/04/2011	17h20	Zacks	Cancer Study to Continue at SPPI - Analyst Blog	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/03/2011	14h00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/03/2011	12h35	Marketwired	Speculative Biotech Firms Remain Popular Takeover Targets	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	22h20	Edgar (US Regulatory)	Annual Report (10-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	22h00	Business Wire	Allos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Pre...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2011	22h00	Business Wire	Allos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/02/2011	15h00	Business Wire	Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/02/2011	20h37	Edgar (US Regulatory)	Statement of Ownership (SC 13G)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2011	00h31	Business Wire	Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/01/2011	14h00	Business Wire	Allos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business Priorities	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/12/2010	14h00	Business Wire	Allos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/12/2010	14h00	Business Wire	Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)